Pressmeddelanden från QLife

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Qlife announces the outcome of the rights issue and resolves on a directed issue of shares to guarantors 24 mar 08:30

Qlife announces the outcome of the rights issue and resolves on a directed issue of shares to guarantors 17 mar 09:00

Qlife provides business update on clinical progress, partnerships and commercialization initiatives 17 mar 09:00

Qlife provides business update on clinical progress, partnerships and commercialization initiatives 17 mar 08:45

The subscription period in Qlife’s rights issue ends on Thursday, 19 March 2026 17 mar 08:45

The subscription period in Qlife’s rights issue ends on Thursday, 19 March 2026 13 mar 08:30

Hipro to accelerate Egoo development and regulatory approval in China following strong interest 13 mar 08:30

Hipro to accelerate Egoo development and regulatory approval in China following strong interest 05 mar 08:50

The subscription period in Qlife’s rights issue begins today 05 mar 08:50

The subscription period in Qlife’s rights issue begins today 04 mar 08:40

Qlife publishes information document due to upcoming rights issue 04 mar 08:40

Qlife publishes information document due to upcoming rights issue 27 feb 18:20

Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors 27 feb 18:20

Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors 26 feb 11:05

Kommuniké från extra bolagsstämma 2026 i Qlife Holding AB 26 feb 11:05

Bulletin from Extraordinary General Meeting 2026 of Qlife Holding AB 25 feb 08:30

Qlife launches pharmacy pilot project in Nordic markets 25 feb 08:30

Qlife launches pharmacy pilot project in Nordic markets 19 feb 18:03

Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife’s ongoing rights issue 19 feb 18:03

Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife’s ongoing rights issue 11 feb 08:30

QLIFE HOLDING AB, Interim Report Q4, October - December 2025 11 feb 08:30

QLIFE HOLDING AB, Interim Report Q4, October - December 2025 26 jan 10:56

Kallelse till extra bolagsstämma 2026 i Qlife Holding AB 26 jan 10:56

Notice of Extraordinary General Meeting 2026 in Qlife Holding AB 26 jan 08:30

Qlife submits Egoo PHE home testing system for regulatory approval 26 jan 08:30

Qlife submits Egoo PHE home testing system for regulatory approval 22 jan 20:50

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7 22 jan 20:50

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7 19 jan 08:30

Qlife prepares for pharmacy testing in Nordic markets 19 jan 08:30

Qlife prepares for pharmacy testing in Nordic markets 15 jan 08:30

Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships 15 jan 08:30

Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships 23 dec 2025 08:30

Qlife provides end-year operational update on key issues 23 dec 2025 08:30

Qlife provides end-year operational update on key issues 16 dec 2025 08:31

Qlife and Hipro sign exclusive commercial agreement covering Qlife’s sale of Hipro products in EU and US markets 16 dec 2025 08:31

Qlife and Hipro sign exclusive commercial agreement covering Qlife’s sale of Hipro products in EU and US markets 16 dec 2025 08:30

The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established 16 dec 2025 08:30

The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established 12 dec 2025 08:30

Egoo Health powers AI-driven personalized diabetes management in China 12 dec 2025 08:30

Egoo Health powers AI-driven personalized diabetes management in China 05 dec 2025 11:13

Qlife’s Birmingham PKU clinical trial published with strong results – key milestone toward CE-mark submission and market launch 05 dec 2025 11:13

Qlife’s Birmingham PKU clinical trial published with strong results – key milestone toward CE-mark submission and market launch 14 nov 2025 17:37

Update on the reverse takeover process – “Red Chip” structure will not be approved by Nasdaq – other structures are pursued 14 nov 2025 17:37

Update on the reverse takeover process – “Red Chip” structure will not be approved by Nasdaq – other structures are pursued 12 nov 2025 08:30

QLIFE HOLDING AB, Interim Report Q3, July - September 2025 12 nov 2025 08:30

QLIFE HOLDING AB, Interim Report Q3, July - September 2025 05 okt 2025 17:00

The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended 05 okt 2025 17:00

The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended 22 sep 2025 18:00

Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 22 sep 2025 18:00

Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 15 sep 2025 08:30

Qlife announces additional product line and progresses two new tests into clinical trials 15 sep 2025 08:30

Qlife announces additional product line and progresses two new tests into clinical trials 27 aug 2025 08:30

QLIFE HOLDING AB, Interim Report Q2, April to June 2025 27 aug 2025 08:30

QLIFE HOLDING AB, Interim Report Q2, April to June 2025 27 aug 2025 08:00

Progress update on the reverse takeover process between Qlife and Hipro 27 aug 2025 08:00

Progress update on the reverse takeover process between Qlife and Hipro 21 aug 2025 18:22

Qlife Holding AB increases existing credit facility and extends the maturity date 21 aug 2025 18:22

Qlife Holding AB increases existing credit facility and extends the maturity date 21 aug 2025 09:13

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product 21 aug 2025 09:13

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product 21 aug 2025 08:30

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product 21 aug 2025 08:30

Qlife together with Birmingham Women’s and Children’s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product 09 jul 2025 22:09

Qlife resolves to carry out a directed set-off issue of approximately SEK 2.47 million in accordance with previously announced credit facility agreement 09 jul 2025 22:09

Qlife resolves to carry out a directed set-off issue of approximately SEK 2.47 million in accordance with previously announced credit facility agreement 05 jun 2025 08:00

Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover 05 jun 2025 08:00

Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover 28 maj 2025 12:18

Kommuniké från årsstämma 2025 i Qlife Holding AB 28 maj 2025 12:18

Bulletin from the annual general meeting 2025 of Qlife Holding AB 20 maj 2025 08:30

QLIFE HOLDING AB, Interim Report Q1, January to March 2025 20 maj 2025 08:30

QLIFE HOLDING AB, Interim Report Q1, January to March 2025 07 maj 2025 09:01

Qlife Holding AB publishes Annual Report for 2024 07 maj 2025 09:01

Qlife Holding AB publicerar årsredovisning för 2024 25 apr 2025 11:26

Kallelse till årsstämma 2025 i Qlife Holding AB 25 apr 2025 11:26

Kallelse till årsstämma 2025 i Qlife Holding AB 10 apr 2025 13:00

Qlife announces strategic roadmap update 10 apr 2025 13:00

Qlife announces strategic roadmap update 25 mar 2025 09:00

Qlife announces that it has received approval from UK authorities to initiate a clinical trial in the UK 25 mar 2025 09:00

Qlife announces that it has received approval from UK authorities to initiate a clinical trial in the UK 21 mar 2025 10:32

Bulletin from the extraordinary general meeting in Qlife Holding AB on 21 March 2025 21 mar 2025 10:32

Kommuniké från extra bolagsstämma i Qlife Holding AB den 21 mars 2025 14 mar 2025 17:45

Qlife announces the last day of trading in BTA 14 mar 2025 17:45

Qlife announces the last day of trading in BTA 05 mar 2025 11:31

Qlife carries out a directed issue to guarantors in connection with the completed rights issue and a directed issue of warrants to JEQ Capital AB 05 mar 2025 11:31

Qlife carries out a directed issue to guarantors in connection with the completed rights issue and a directed issue of warrants to JEQ Capital AB 04 mar 2025 10:45

Qlife reaffirms its strategy and plans to expand the Board with three new members 04 mar 2025 10:45

Qlife reaffirms its strategy and plans to expand the Board with three new members 04 mar 2025 10:40

Notice of Extraordinary General Meeting 2025 in Qlife Holding AB 04 mar 2025 10:40

Kallelse till extra bolagsstämma i Qlife Holding AB 26 feb 2025 19:27

Qlife announces outcome in rights issue 26 feb 2025 19:27

Qlife announces outcome in rights issue 21 feb 2025 10:00

The subscription period in Qlife’s rights issue ends on Tuesday, 25 February 2025 21 feb 2025 10:00

The subscription period in Qlife’s rights issue ends on Tuesday, 25 February 2025 21 feb 2025 09:00

Qlife has successfully verified the biomarkers related to the previously announced LOI 21 feb 2025 09:00

Qlife has successfully verified the biomarkers related to the previously announced LOI 17 feb 2025 09:00

Qlife announces the launch of Egoo.AI and the start of sales for the Women’s Health platform 17 feb 2025 09:00

Qlife announces the launch of Egoo.AI and the start of sales for the Women’s Health platform 14 feb 2025 09:00

Qlife launches Thyroid Disease and Vitamin D biomarkers, now available for immediate sales 14 feb 2025 09:00

Qlife launches Thyroid Disease and Vitamin D biomarkers, now available for immediate sales 12 feb 2025 08:00

Members of the Board of Directors and management intend to subscribe in the ongoing rights issue 12 feb 2025 08:00

Members of the Board of Directors and management intend to subscribe in the ongoing rights issue